Search results for " Chronic [Medical Subject Headings]"

showing 10 items of 272 documents

Dietary phytochemicals in the protection against oxysterol-induced damage.

2017

The intake of fruits and vegetables is associated with reduced incidence of many chronic diseases. These foods contain phytochemicals that often possess antioxidant and free radical scavenging capacity and show anti-inflammatory action, which are also the basis of other bioactivities and health benefits, such as anticancer, anti-aging, and protective action for cardiovascular diseases, diabetes mellitus, obesity and neurodegenerative disorders. Many factors can be included in the etiopathogenesis of all of these multifactorial diseases that involve oxidative stress, inflammation and/or cell death processes, oxysterols, i.e. cholesterol oxidation products (COPs) as well as phytosterol oxidat…

0301 basic medicineAntioxidantOxysterolmedicine.medical_treatmentPhytochemicalsContext (language use)PhytochemicalPharmacologymedicine.disease_causeBiochemistryAntioxidants03 medical and health scienceschemistry.chemical_compoundOxysterol0302 clinical medicineDiabetes mellitusmedicinePhytosterol oxidation productAnimalsHumansCholesterol oxidation productMolecular BiologyCell DeathAnimalCholesterolPhytosterolOrganic ChemistryHuman chronic diseaseCell BiologyOxysterolsmedicine.diseaseObesity030104 developmental biologyBiochemistrychemistry030220 oncology & carcinogenesisChronic DiseaseAntioxidantOxidative stressHumanChemistry and physics of lipids
researchProduct

Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study

2018

Background The CD4/CD8 ratio has been associated with the risk of AIDS and non-AIDS events. We describe trends in immunological parameters in people who underwent a switch to monotherapy or dual therapy, compared to a control group remaining on triple antiretroviral therapy (ART). Methods We included patients in Icona who started a three-drug combination ART regimen from an ART-naïve status and achieved a viral load ≤ 50 copies/mL; they were subsequently switched to another triple or to a mono or double regimen. Standard linear regression at fixed points in time (12-24 months after the switch) and linear mixed model analysis with random intercepts and slopes were used to compare CD4 and CD8…

0301 basic medicineMaleCD4-CD8 Ratiolcsh:MedicineHIV InfectionsCD8-Positive T-LymphocytesCD4/CD8 ratio; CD8; Chronic inflammation; Dual therapy; Monotherapy; Adult; Anti-HIV Agents; CD4-CD8 Ratio; CD8-Positive T-Lymphocytes; Cohort Studies; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Tenofovir; Medicine (all)Cohort Studies0302 clinical medicineEmtricitabineHIV Infection030212 general & internal medicineMedicine (all)General MedicineChronic inflammationCD4/CD8 ratio; CD8; Chronic inflammation; Dual therapy; Monotherapy; Medicine (all)Middle AgedSettore MED/07 - Microbiologia e Microbiologia ClinicaReverse Transcriptase InhibitorReverse Transcriptase InhibitorsFemalecd4/cd8 ratio; cd8; chronic inflammation; dual therapy; monotherapy; medicine (all)Research Articlemedicine.drugCohort studyHumanAdultmedicine.medical_specialtyDual therapyCD4/CD8 ratio; CD8; Chronic inflammation; Dual therapy; Monotherapy; Adult; Anti-HIV Agents; CD4-CD8 Ratio; CD8-Positive T-Lymphocytes; Cohort Studies; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; TenofovirAnti-HIV Agents030106 microbiologyCD4-CD8 RatioEmtricitabineSettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciencesCD4/CD8 ratioInternal medicineLinear regressionmedicineHumansDual therapyTenofovirbusiness.industrylcsh:RAnti-HIV AgentCD8CD8-Positive T-LymphocyteMonotherapyConfidence intervalRegimenCD4/CD8 ratio; CD8; Chronic inflammation; Dual therapy; MonotherapyCD8; CD4/CD8 ratio; Chronic inflammation; Monotherapy; Dual therapyCohort StudiebusinessCD8
researchProduct

IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia.

2017

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Its clinical course is typically indolent; however, based on a series of pathobiological, clinical, genetic, and phenotypic parameters, patient survival varies from less than 5 to more than 20 years. In this paper, we show for the first time that the expression of the interferon-inducible DNA sensor IFI16, a member of the PYHIN protein family involved in proliferation inhibition and apoptosis regulation, is associated with the clinical outcome in CLL. We studied 99 CLLs cases by immunohistochemistry and 10 CLLs cases by gene expression profiling. We found quite variable degrees of IFI16 expression among CLLs cases. No…

0301 basic medicineMaleChronic lymphocytic leukemiaGene Expressionhemic and lymphatic diseasesGene expression80 and overImmunology and AllergyChronicNuclear ProteinCD20Aged 80 and overLeukemiaMembrane GlycoproteinsZAP-70 Protein-Tyrosine KinasebiologyZAP70Nuclear ProteinsGeneral MedicineMiddle AgedPhenotypeImmunohistochemistryLymphocyticchronic lymphocytic leukemia; gene expression; IFI16; immunohistochemistry; prognosis; ZAP70; Adult; Aged; Aged 80 and over; Antigens CD38; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Leukemia Lymphocytic Chronic B-Cell; Male; Membrane Glycoproteins; Middle Aged; Nuclear Proteins; Phosphoproteins; Treatment Outcome; Young Adult; ZAP-70 Protein-Tyrosine Kinase; Gene Expression; Immunology and Allergy; 2734; Microbiology (medical)LeukemiaTreatment OutcomePhosphoproteinimmunohistochemistryImmunohistochemistryZAP70FemaleMembrane GlycoproteinprognosiHumanMicrobiology (medical)Adult2734IFI16; ZAP70; chronic lymphocytic leukemia; gene expression; immunohistochemistry; prognosisNOPathology and Forensic Medicine03 medical and health sciencesYoung AdultmedicineHumansAntigensIFI16Agedbusiness.industryGene Expression ProfilingB-Cellchronic lymphocytic leukemia; gene expression; IFI16; immunohistochemistry; prognosis; ZAP70; ADP-ribosyl Cyclase 1; Adult; Aged; Aged 80 and over; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Leukemia Lymphocytic Chronic B-Cell; Male; Membrane Glycoproteins; Middle Aged; Nuclear Proteins; Phosphoproteins; Treatment Outcome; Young Adult; ZAP-70 Protein-Tyrosine Kinase; Gene Expression; 2734; Immunology and Allergy; Microbiology (medical)medicine.diseasePhosphoproteinsADP-ribosyl Cyclase 1Leukemia Lymphocytic Chronic B-CellGene expression profilingchronic lymphocytic leukemia; gene expression; IFI16; immunohistochemistry; prognosis; ZAP70; Immunology and Allergy; 2734; Microbiology (medical)030104 developmental biologygene expressionCancer researchbiology.proteinchronic lymphocytic leukemiaprognosisbusinessCD38APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
researchProduct

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVI…

2021

Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and …

0301 basic medicineMaleClinical BiochemistryDiseaseCohort Studies0302 clinical medicineDrug DiscoveryReceptors80 and overMedicineAged 80 and overeducation.field_of_studyIncidence (epidemiology)IncidenceInterleukin-17psoriasisMiddle Ageddermatologysars-CoV-2Italybiological therapy030220 oncology & carcinogenesisCohortBiological ProductCOVID-19; biological therapy; dermatology; psoriasis; sars-CoV-2FemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2; Adult; Aged; Aged 80 and over; Biological Products; Biological Therapy; COVID-19; Chronic Disease; Cohort Studies; Female; Humans; Incidence; Interleukin-17; Italy; Male; Middle Aged; Pandemics; Psoriasis; Receptors Interleukin; Risk Assessment; Tumor Necrosis Factor-alpha; Young AdultCohort studyHumanAdultmedicine.medical_specialtyPopulationRisk AssessmentCOVID-19; psoriasis; biological therapy; dermatology; sars-CoV-203 medical and health sciencesYoung AdultSettore MED/35Internal medicinePsoriasisPsoriasis.HumanseducationPandemicsAgedPharmacologyPsoriasiBiological ProductsPandemicbiological therapy; COVID-19; dermatology; psoriasis; sars-CoV-2business.industryTumor Necrosis Factor-alphaCOVID-19Receptors InterleukinBiological productInterleukinmedicine.diseaseClinical trial030104 developmental biologyChronic DiseaseCOVID-19; SARS-CoV-2; biological therapy; dermatology; psoriasisCohort Studiebusiness
researchProduct

Verrucous Plaque With Unusually Large Candida Blastoconidia: A Unique Clinicopathological Presentation of Systemic Mucocutaneous Candidiasis.

2018

Mucocutaneous candidiasis is a common infection affecting both immunocompetent and immunosuppressed individuals. Diversity in the clinical and histopathological presentation of mucocutaneous candidiasis is well known. However, the occurrence of cutaneous verrucous lesions and giant yeast-like structures has been rarely reported. In this article, we describe a case of disseminated mucocutaneous candidiasis in an immunosuppressed patient who presented as a verrucous plaque on the scrotum with giant Candida blastoconidia. This peculiar presentation expands the clinicopathological spectrum of mucocutaneous candidiasis and highlights the wide range of clinical manifestations and great morphologi…

0301 basic medicineMalemedicine.medical_specialtyAdolescent030106 microbiologychronic mucocutaneous candidiasisDermatologyMucocutaneous CandidiasisBlastoconidiumPathology and Forensic MedicinePrecursor Cell Lymphoblastic Leukemia Lymphoma030207 dermatology & venereal diseases03 medical and health sciencesImmunocompromised Host0302 clinical medicinegiant blastoconidiaScrotummedicineHumansCandidiasis chronic mucocutaneousCandidabusiness.industryCandidiasis Chronic MucocutaneousHematopoietic Stem Cell TransplantationVerrucous LesionGeneral Medicineatypical candidiasisPrecursor Cell Lymphoblastic Leukemia-LymphomaSpores FungalDermatologymedicine.anatomical_structurecandidaScrotumPresentation (obstetrics)businessThe American Journal of dermatopathology
researchProduct

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors

2019

In Chronic Myeloid Leukemia (CML), successful treatment requires accurate molecular monitoring to evaluate disease response and provide timely interventions for patients failing to achieve the desired outcomes. We wanted to determine whether measuring BCR-ABL1 mRNA doubling-times (DTs) could distinguish inconsequential rises in the oncogene’s expression from resistance to tyrosine kinase inhibitors (TKIs). Thus, we retrospectively examined BCR-ABL1 evolution in 305 chronic-phase CML patients receiving imatinib mesylate (IM) as a first line treatment. Patients were subdivided in two groups: those with a confirmed rise in BCR-ABL1 transcripts without MR3.0 loss and those failing IM. We found …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyDisease ResponseChronic Myeloid LeukemiaBCR-ABL1/ABL1IShalving-timelcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicinehemic and lymphatic diseasesBCR-ABL1/ABL1; IS; Chronic Myeloid Leukemia; Doubling-time; Halving-time; Tyrosine kinase inhibitorstyrosine kinase inhibitorsmedicineDoubling timeOriginal ResearchBCR-ABL1/ABL1Oncogenebusiness.industryMyeloid leukemialcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensDiscontinuationdoubling-time030104 developmental biologyImatinib mesylateOncology030220 oncology & carcinogenesisCohortISBCR-ABL1/ABL1 ISbusinessTyrosine kinaseFrontiers in Oncology
researchProduct

Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review

2021

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by a fusion gene, encoding for the chimeric protein BCR-ABL, with constitutive tyrosine kinase activity. The use of tyrosine kinase inhibitors (TKIs) has drastically improved survival, but there are significant concerns about cardiovascular toxicity. Cardiovascular risk can be lowered with appropriate baseline evaluation, accurate choice of TKI therapy, improvement of modifiable cardiovascular risk factors through lifestyle modifications, and prescription of drugs for primary or secondary prevention. Which examinations are necessary, and when do they have to be scheduled? How often should a TKI-treated patient undergo wh…

0301 basic medicineOncologycardiovascular riskmedicine.medical_specialtychronic myelocytic leukemiacardio-oncologyPhysiologyReviewSettore MED/15 - Malattie Del Sangue03 medical and health sciencescardiovascular events0302 clinical medicineInternal medicinePhysiology (medical)hemic and lymphatic diseasesmedicineNeoplasmQP1-981Medical prescriptionAdverse effectMyeloproliferative neoplasmHematologyMechanism (biology)business.industryMyeloid leukemiamedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolarerespiratory tract diseasestyrosine kinase inhibitions therapy030104 developmental biology030220 oncology & carcinogenesiscardiovascular events chronic myelocytic leukemia cardiovascular risk cardio-oncology tyrosine kinase inhibitions therapybusinessTyrosine kinaseFrontiers in Physiology
researchProduct

Influenza vaccine effectiveness among high-risk groups: a systematic literature review and metaanalysis of case-control and cohort studies

2017

Vaccination represents the most effective intervention to prevent infection, hospitalization and mortality due to influenza. This meta-analysis quantifies data reporting influenza vaccine effectiveness (VE) on influenza visits and hospitalizations of case-control and cohort studies among high-risk groups. A systematic literature review including original articles published between 2007 and 2016, using a protocol registered on Prospero with No. 42017054854, and a meta-analysis were conducted. For three high-risk groups (subjects with underlying health conditions, pregnant women and health care workers) only a qualitative evaluation was carried out. The VE quantitative analysis demonstrated a…

0301 basic medicineReviewSettore MED/42 - Igiene Generale E ApplicataCohort Studies0302 clinical medicinePregnancyvaccineHealth careImmunology and AllergyMedicine030212 general & internal medicineData reportingChildAged 80 and overVaccinationMiddle AgedVaccinationHospitalizationSystematic reviewInfluenza VaccinesMeta-analysisChild PreschoolFemaleelderly subjectsinfluenzaCohort studyAdultRiskmedicine.medical_specialtyInfluenza vaccine effectiveness children elderly subjects chronic disease pregnancy health care worker hospitalization visit.AdolescentInfluenza vaccine030106 microbiologyImmunologyeffectiveness03 medical and health sciencesYoung AdultchildrenInfluenza HumanHumansIntensive care medicineAgedPharmacologybusiness.industryPublic healthInfanthealth care workerCase-Control StudiesEmergency medicinebusinessvisitchronic disease
researchProduct

From Genesis to Revelation: The Role of Inflammatory Mediators in Chronic Respiratory Diseases and their Control by Nucleic Acid-based Drugs.

2015

Asthma, chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis, are among the most common chronic diseases and their prevalence is increasing. Each of these diseases is characterized by the secretion of cytokines and pro-inflammatory molecules which are thought to play a critical role in their pathogenesis. Moreover, immune cells, particularly neutrophils, macrophages and dendritic cells as well structural cells such as epithelial and airway smooth muscle cells are also involved in the pathogenic cycle of these diseases. There is a pressing need for the development of new therapies for these pulmonary diseases, particularly as no existing treatment has bee…

0301 basic medicineSmall interfering RNARespiratory diseasessiRNA deliveryHMGB1 (high-mobility group box 1)medicine.medical_treatmentGenetic enhancementOligonucleotidesPharmaceutical Science02 engineering and technologyBiologySmall InterferingPathogenesis03 medical and health sciencesIdiopathic pulmonary fibrosisImmune systemRNA interferenceNucleic AcidsmedicineAnimalsHumansAntisenseHMGB1 ProteinRNA Small InterferingCatalyticLungNABDs deliveryDNADNA CatalyticGenetic TherapyOligonucleotides Antisense021001 nanoscience & nanotechnologymedicine.diseaseRespiration Disorders030104 developmental biologyCytokinemedicine.anatomical_structureImmunologyChronic DiseaseRNAInflammation Mediators0210 nano-technologyHMGB1 (high-mobility group box 1); Inflammation mediators; NABDs delivery; Respiratory diseases; siRNA delivery; Animals; Chronic Disease; DNA Catalytic; HMGB1 Protein; Humans; Inflammation Mediators; Nucleic Acids; Oligonucleotides Antisense; RNA Small Interfering; Respiration Disorders; Genetic TherapyCurrent drug delivery
researchProduct

Real life experiences in HCV management in 2018

2019

Introduction: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct-acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient’s identification, universal access to antiviral therapy and treatment optimiza…

0301 basic medicinehepatitis C virusSofosbuvirSustained Virologic ResponseAntiviral therapyAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Microbiology; Microbiology (medical); Infectious Diseases; Virologymedicine.disease_causeChronic liver diseaseHealth Services Accessibility0302 clinical medicinedirect acting antiviralshepatitis C viruMass Screening030212 general & internal medicineChronicComputingMilieux_MISCELLANEOUSHepatitis CHepatitis BHepatitis CPibrentasvirAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C Chronic; Humans; Italy; Mass Screening; Sustained Virologic ResponseInfectious DiseasesItalyHCVDisease ProgressionAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C; Chronic; Humans; Italy; Mass Screening; Sustained Virologic Responsemedicine.drugHumanMicrobiology (medical)Settore MED/17 - Malattie InfettiveHepatitis C virus030106 microbiologyInfectious DiseaseAntiviral AgentsMicrobiology03 medical and health sciencesVirologymedicineHumansAntiviral therapy; DAAs; HCV; chronic liver disease; direct acting antivirals; hepatitis C virusMass screeningDAAHepatitis B virusAntiviral Agentbusiness.industrychronic liver diseaseDAAsHepatitis C Chronicmedicine.diseaseVirologybusiness
researchProduct